⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Form 8-K
sec.gov
ROIV
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
globenewswire.com
ROIV
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
globenewswire.com
IMVT
ROIV
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
globenewswire.com
ROIV
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
globenewswire.com
IMVT
ROIV
CART
NVS
MRK
REGN
UCB
JNJ
AMGN
ARGX
KYMR
CABA
BMY
BHVN
Form 8-K
sec.gov
ROIV
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
globenewswire.com
ROIV
ROIVW
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
globenewswire.com
ROIV
ROIVW
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
globenewswire.com
ROIV
ROIVW
Form 8-K/A
sec.gov
ROIV